medigraphic.com

2016, Número S1

<< Anterior Siguiente >>

Rev Mex Anest 2016; 39 (S1)


Alternativas en el manejo de la hemorragia aguda en el transoperatorio

Martínez-de los Santos CA, Espinoza de los Monteros-Estrada I

Idioma: Español
Referencias bibliográficas: 35
Paginas: 276-280
Archivo PDF: 176.77 Kb.


FRAGMENTO

El manejo clínico de hemorragia grave en la cirugía y después de un trauma sigue siendo un reto importante. La hemorragia es la principal causa de paro cardíaco que se desarrolla dentro de las salas de quirófano. Son muchos los factores humanos involucrados en el proceso que conduce al desarrollo de una hemorragia a un grado crítico y dentro de los que se incluyen el procedimiento quirúrgico, las prácticas transfusionales, el abastecimiento de sangre y el manejo anestésico. Las transfusiones de plaquetas alogénicas y plasma son ampliamente utilizados para reemplazar componentes celulares y humorales de coagulación. Estos productos alogénicos parecen estar salvando vidas cuando se utilizan en forma temprana en el protocolo de transfusión masiva en la que más de 6 a 10 unidades de glóbulos rojos se administran típicamente en 12-24 h.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Tanaka K, Mazzeffi M, Durila M. Role of prothrombin complex concentrate in perioperative coagulation therapy. J Intensive Care. 2014;2:60.

  2. Peña-Pérez C, Carrillo-Esper R. Manejo de la hemorragia aguda en el transoperatorio. Rev Mex Anest. 2014;37:S400-S406.

  3. Holcomb JB, Wade CE, Michalek JE, Chisholm GB, Zarzabal LA, Schreiber MA, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg. 2008;248:447-458.

  4. Inaba K, Lustenberger T, Rhee P, Holcomb JB, Blackbourne LH, Shulman I, et al. The impact of platelet transfusion in massively transfused trauma patients. J Am Coll Surg. 2010;211:573-579.

  5. Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB, Teixeira PG, et al. Impact of plasma transfusion in trauma patients who do not require massive transfusion. J Am Coll Surg. 2010;210:957-965.

  6. Watson GA, Sperry JL, Rosengart MR, Minei JP, Harbrecht BG, Moore EE, et al. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma. 2009;67:221-227.

  7. Inaba K, Branco BC, Rhee P, Holcomb JB, Blackbourne LH, Shulman I, et al. Impact of ABO-identical vs ABO-compatible nonidentical plasma transfusion in trauma patients. Arch Surg. 2010;145:899-906.

  8. The Japanese Society of Anesthesiologists. Report of the survey 2004-2008. Available in: https://member.anesth.or.jp/App/datura/news2010/r20100301.html

  9. Irita K, Kawashima Y, Morita K, Seo N, Iwao Y, Sanuki M, et al. Supplemental survey in 2003 concerning life-threatening hemorrhagic events in the operating room. Masui. 2005;54:77-86.

  10. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologist Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology. 2006;105:198-208.

  11. British Committee for Standards in Haematology, Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. Guidelines on the management of massive blood loss. Br J Haematol. 2006;135:634-641.

  12. Weiskopf RB, Viele MK, Feiner J, Kelley S, Lieberman J, Noorani M, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA. 1998;279:217-221.

  13. Irita K, Inada E. Guidelines for management of critical bleeding in obstetrics. Masui. 2011;60:14-22.

  14. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding. Guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013;30:270-382.

  15. Mellin-Olsen J, Staender S, Whitaker DK, Smith AF. The Helsinki declaration on patient safety in anesthesiology. Eur J Anaesthesiol. 2010;27:592-597.

  16. Murray DJ, Pennell BJ, Weinstein SL, Olson JD. Packed red cells in acute blood loss: dilutional coagulopathy as a cause of surgical bleeding. Anesth Analg. 1995;80:336-342.

  17. World Health Organization (WHO). 63rd World Health Assembly. Availability, safety and quality of blood products. 2010 [accessed 22 October 2013]. Available in: http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R12-en.pdf

  18. American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice. Guidelines for Perioperative Blood Management. An Updated Report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology. 2015;122:241-275.

  19. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet. 2007;370:439-448.

  20. Lin DM, Murphy LS, Tran MH. Use of prothrombin complex concentrates and fibrinogen concentrates in the perioperative setting: a systematic review. Transfus Med Rev. 2013;27:91-104.

  21. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363:1791-1800.

  22. Franchini M, Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus. 2012;10:23-27.

  23. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3:1894-1904.

  24. Tziomalos K, Vakalopoulou S, Perifanis V, Garipidou V. Treatment of congenital fibrinogen deficiency: overview and recent findings. Vasc Health Risk Manag. 2009;5:843-848.

  25. Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfus Med. 2008;18:151-157.

  26. O’Shaughnessy DF, Atterbury C, Bolton Maggs P, et al; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11-28.

  27. Sørensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol. 2010;149:834-843.

  28. Rahe-Meyer N, Sørensen B. Fibrinogen concentrate for management of bleeding. J Thromb Haemost. 2011;9:1-5.

  29. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica. 2007;92:846-849.

  30. Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organization. Haemophilia. 2004;10:593-628.

  31. Fenger-Erikson C, Ingerslev J, Sørenson B. Fibrinogen concentrate - a potential universal haemostatic agent. Expert Opin Biol Ther. 2009;9:1325-1333.

  32. Negrier C, Rothschild C, Goudemand J, et al. Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate. J Thromb Haemost. 2008;6:1494-1499.

  33. Kreuz W, Meili E, Peter-Salonen K, et al. Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfus Apher Sci. 2005;32:239-246.

  34. Kreuz W, Meili E, Peter-Salonen K, et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci. 2005;32:247-253.

  35. Bell SF, Rayment R, Collins PW, Collis RE. The use of fibrinogen concentrate to correct hypofibrinogenemia rapidly during obstetric haemorrhage. Int J Obstet Anaesth. 2010;19:218-223.




2020     |     www.medigraphic.com